Urogen Pharma (NASDAQ:URGN – Get Free Report) is one of 894 public companies in the “Pharmaceuticals” industry, but how does it compare to its competitors? We will compare Urogen Pharma to related businesses based on the strength of its earnings, institutional ownership, profitability, dividends, valuation, analyst recommendations and risk.
Earnings and Valuation
This table compares Urogen Pharma and its competitors revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Urogen Pharma | $109.79 million | -$153.49 million | -22.57 |
| Urogen Pharma Competitors | $3.56 billion | $3.19 billion | 555.16 |
Urogen Pharma’s competitors have higher revenue and earnings than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Analyst Recommendations
This is a summary of current ratings for Urogen Pharma and its competitors, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Urogen Pharma | 1 | 1 | 8 | 0 | 2.70 |
| Urogen Pharma Competitors | 7850 | 13806 | 25845 | 1039 | 2.41 |
Urogen Pharma presently has a consensus price target of $53.38, indicating a potential upside of 79.17%. As a group, “Pharmaceuticals” companies have a potential upside of 27.58%. Given Urogen Pharma’s stronger consensus rating and higher probable upside, analysts clearly believe Urogen Pharma is more favorable than its competitors.
Risk & Volatility
Urogen Pharma has a beta of 1.68, suggesting that its stock price is 68% more volatile than the S&P 500. Comparatively, Urogen Pharma’s competitors have a beta of -0.05, suggesting that their average stock price is 105% less volatile than the S&P 500.
Profitability
This table compares Urogen Pharma and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Urogen Pharma | -26.27% | N/A | -26.88% |
| Urogen Pharma Competitors | -2,391.70% | -206.08% | -14.88% |
Insider and Institutional Ownership
91.3% of Urogen Pharma shares are held by institutional investors. Comparatively, 32.6% of shares of all “Pharmaceuticals” companies are held by institutional investors. 4.8% of Urogen Pharma shares are held by company insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Urogen Pharma beats its competitors on 7 of the 13 factors compared.
About Urogen Pharma
UroGen Pharma Ltd. is a biopharmaceutical company focused on developing and commercializing treatments for cancers of the urinary tract. Its work centers on therapies delivered directly to the urinary system, including treatments for certain forms of urothelial cancer. The company’s products include Jelmyto, a mitomycin-based treatment delivered to the upper urinary tract for adults with low-grade upper tract urothelial cancer, and Zusduri, a mitomycin-based treatment for adults with recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer.
Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
